Spread The Word

News Releases

Date Title and Summary Additional Formats
Toggle Summary Clementia Initiates Pivotal Phase 3 MOVE Trial for Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva
Patient Dosing Has Commenced; Registration Study to Enroll 80 Patients Worldwide Company to Host Conference Call at 8:30am ET Today MONTREAL , Dec. 12, 2017 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical-stage biopharmaceutical company innovating new treatments for
View HTML
Toggle Summary Clementia Announces Date of Corporate Update Conference Call
MONTREAL , Dec. 05, 2017 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical-stage biopharmaceutical company, today announced that management will host a conference call and webcast at 8:30 a.m. ET on Tuesday, Dec. 12, 2017 , to provide a corporate update and discuss recent
View HTML
Toggle Summary Clementia Reports Third Quarter 2017 Financial Results and Business Highlights
Initial Public Offering Completed, Raising $128.2 Million in Net Proceeds U.S. FDA Grants Breakthrough Therapy Designation to Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP) On Track to Begin Pivotal MOVE Study in FOP Later this Year MONTREAL , Nov.
View HTML
Toggle Summary Clementia Pharmaceuticals to Participate in Upcoming Investor Conferences
MONTREAL , Sept. 06, 2017 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical stage biopharmaceutical company, today announced that Dr. Clarissa Desjardins , CEO of Clementia Pharmaceuticals , will participate in two upcoming investor conferences: Morgan Stanley 15 th
View HTML
Toggle Summary Clementia Announces Data Presentations at Upcoming Medical Conferences in September
MONTREAL , Aug. 31, 2017 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical stage biopharmaceutical company, today announced upcoming data presentations highlighting our palovarotene development efforts at the 2017 American Society for Bone and Mineral Research (ASBMR)
View HTML
Toggle Summary Clementia Announces Closing of Over-Allotment Option in its Initial Public Offering
MONTREAL , Aug. 21, 2017 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) (the “Company” or “Clementia”), a clinical stage biopharmaceutical company, today announced that the underwriters of its previously announced initial public offering exercised their option to purchase an
View HTML
Toggle Summary Clementia Announces Pricing of Initial Public Offering
MONTREAL , Aug. 2, 2017 /PRNewswire/ --  Clementia Pharmaceuticals Inc. (NASDAQ: CMTA) (the "Company" or "Clementia"), a clinical stage biopharmaceutical company, today announced the pricing of its initial public offering of 8,000,000 common shares at an initial public offering price of $15 .00 per
View HTML
Toggle Summary Phase 2 Part A Open Label Extension Trial of Palovarotene for Treatment of Patients with Fibrodysplasia Ossificans Progressiva Continues Positive Trends
MONTREAL, CANADA, March 28, 2017  – Clementia Pharmaceuticals Inc. today announced the preliminary results of its Phase 2 Part A Open Label Extension (OLE) palovarotene trial in the treatment of fibrodysplasia ossificans progressiva (FOP). All 40 subjects who enrolled into the double-blind,
View HTML
Toggle Summary Clementia Clinical Program: Necker Begins Enrolling Patients in Palovarotene 2B Extension Study
MONTREAL, CANADA, November, 18, 2016  – Clementia is pleased to announce that the Hôpital Necker of Paris is ready to enroll FOP patients into Part B of its Phase 2 Open-label Extension Trial, which is a new study in France called PVO-1A-204. Dr Geneviève Baujat is principal investigator at
View HTML
Toggle Summary Clementia Clinical Program: Queensland University of Technology (QUT) Institute of Health and Biomedical Innovation (IHBI) Begins Enrolling Patients in Palovarotene 2B Extension Study
MONTREAL, CANADA, November, 18, 2016  – Clementia is pleased to announce that the Queensland University of Technology (QUT) Institute of Health and Biomedical Innovation (IHBI) is treating FOP patients in Part B of the Phase 2 Open-label Extension Trial (PVO-1A-202). Prof. Dr.
View HTML